| 199 | -- | 202 | Pawel Moskal, Ewa L. Stepien. New trends in theranostics |
| 203 | -- | 212 | Abass Alavi, Thomas J. Werner, Ewa L. Stepien, Pawel Moskal. Unparalleled and revolutionary impact of PET imaging on research and day to day practice of medicine |
| 213 | -- | 220 | Leszek Królicki, Jolanta Kunikowska. Theranostics - present and future |
| 221 | -- | 226 | Marta Opalinska, Anna Sowa-Staszczak, Ibraheem Al Maraih, Aleksandra Gilis-Januszewska, Alicja Hubalewska-Dydejczyk. Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma |
| 227 | -- | 233 | Ryszard Witold Gryglewski. History of radiotherapy in Poland. A brief outline of the problem |
| 235 | -- | 239 | Tomasz Matulewicz. Radioactive nuclei for β+γ PET and theranostics: selected candidates |
| 241 | -- | 257 | Jaroslaw Choinski, Monika Lyczko. Prospects for the production of radioisotopes and radiobioconjugates for theranostics |
| 259 | -- | 264 | Paulina Cegla, Tomasz Piotrowski. History of positron emission tomography (PET) in Poland |
| 265 | -- | 267 | Stefaan Vandenberghe. Progress and perspectives in total body PET systems instrumentation |
| 269 | -- | 291 | Stan Majewski. Perspectives of brain imaging with PET systems |
| 293 | -- | 300 | Michal Silarski, Katarzyna Dziedzic-Kocurek, Monika Szczepanek. Combined BNCT and PET for theranostics |
| 301 | -- | 309 | Ewa L. Stepien, Carina Rzaca, Pawel Moskal. Novel biomarker and drug delivery systems for theranostics - extracellular vesicles |
| 311 | -- | 319 | Pawel Moskal, Ewa L. Stepien. Positronium as a biomarker of hypoxia |